Drug
Denosumab 60 mg/ml [Prolia]
Denosumab 60 mg/ml [Prolia] is a pharmaceutical drug with 4 clinical trials. Historical success rate of 66.7%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
66.7%
Based on 2 completed trials
Completion Rate
67%(2/3)
Active Trials
0(0%)
Results Posted
50%(1 trials)
Terminated
1(25%)
Phase Distribution
Ph phase_2
3
75%
Ph phase_3
1
25%
Phase Distribution
0
Early Stage
3
Mid Stage
1
Late Stage
Phase Distribution4 total trials
Phase 2Efficacy & side effects
3(75.0%)
Phase 3Large-scale testing
1(25.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
66.7%
2 of 3 finished
Non-Completion Rate
33.3%
1 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(2)
Terminated(1)
Other(1)
Detailed Status
Completed2
unknown1
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
66.7%
Most Advanced
Phase 3
Trials by Phase
Phase 23 (75.0%)
Phase 31 (25.0%)
Trials by Status
completed250%
unknown125%
terminated125%
Recent Activity
0 active trials
Showing 4 of 4
terminatedphase_2
Therapy of the Skeletal Disease of Type 2 Diabetes With Denosumab
NCT03457818
unknownphase_3
Denosumab vs Zoledronate After Lumbar Fusion
NCT05638399
completedphase_2
Denosumab and Osteoporotic Vertebral Compression Fracture
NCT05058443
completedphase_2
Alendronate Versus Denosumab in Kidney Transplant Patients
NCT04169698
Clinical Trials (4)
Showing 4 of 4 trials
NCT03457818Phase 2
Therapy of the Skeletal Disease of Type 2 Diabetes With Denosumab
NCT05638399Phase 3
Denosumab vs Zoledronate After Lumbar Fusion
NCT05058443Phase 2
Denosumab and Osteoporotic Vertebral Compression Fracture
NCT04169698Phase 2
Alendronate Versus Denosumab in Kidney Transplant Patients
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4